Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6813—Hybridisation assays
  • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
  • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
  • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6844—Nucleic acid amplification reactions
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2320/00—Applications; Uses
  • C12N2320/10—Applications; Uses in screening processes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2521/00—Reaction characterised by the enzymatic activity
  • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
  • C12Q2521/313—Type II endonucleases, i.e. cutting outside recognition site
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2527/00—Reactions demanding special reaction conditions
  • C12Q2527/101—Temperature

Definitions

• CRISPR-associated (“Cas”) proteins have been discovered to have a collateral cleavage activity useful in detection (e.g., diagnostic) systems to detect particular nucleic acids of interest. See, for example, review by Sashital Genome Med 2018: 10, 32.
• the present disclosure provides improved detection (e.g., diagnostic) technologies that utilize Cas-protein collateral activity .
• the present disclosure identifies the source of a problem with use of certain Cas enzymes in certain collateral activity assays.
• certain such assays include a step that involves incubation at an elevated temperature for a period of time, and various Cas enzymes may be insufficiently stable to maintain a sufficient level of activity (e.g., collateral activity) under such conditions.
• a step may be or comprise a nucleic acid extension and/or amplification step.
• the present disclosure provides the insight that particularly desirable embodiments of various collateral activity assays are those that can be performed in a single reaction vessel (i.e., so-called “one pot”) assays.
• the present disclosure appreciates that Cas enzymes whose activity (e.g., collateral cleavage activity) is insufficiently stable to maintain sufficient activity through any and all elevated-temperature step(s) (which may be or include, for example, one or more nucleic acid extension and/or amplification step(s)) may not be useful in such one-pot assays.
• the present disclosure furthermore documents that certain Cas protein(s) (e.g., Casl3 and Casl2) are insufficiently stable at relevant temperature(s), e.g., at temperatures at which nucleic acid extension and/or amplification reactions are typically performed (e.g., above about 60-65 °C).
• relevant temperature(s) e.g., at temperatures at which nucleic acid extension and/or amplification reactions are typically performed (e.g., above about 60-65 °C).
• thermostable variants of various Cas proteins e.g., Cas9
• Cas9 have already been described and/or otherwise made publicly available
• Those skilled in the art are able to compare such thermostable variants with related non-thermostable homologs (e.g., orthologs), in order to assess sequence changes and/or elements that may be necessary and/or sufficient to achieve thermostability, and furthermore can identify such sequence changes and/or elements in other homologs (e.g., orthologs) and/or can introduce them thereinto.
• related non-thermostable homologs e.g., orthologs
• thermostable Cas protein is a Cas 12 or
• a useful thermostable Cas protein is a Cas enzyme comprising an amino acid sequence having 80%, 85%, 90%, 99% or 100% sequence identity to any one of SEQ ED Nos. 1-283.
• Cas protein performs (e g., its collateral cleavage activity functions sufficiently) at temperatures above about 50 °C; in some embodiments, above a temperature selected from the group consisting of about 55 °C, about 56 °C, about 57 °C, about 58 °C, about 59 °C, about 60 °C, about 61 °C, about 62 °C, about 63 °C, about 64 °C, about 65 °C, about 66 °C, about 67 °C, about 68 °C, about 69 °C, about 70 °C, about 71 °C, about 72 °C, about 73 °C, about 74 °C, about 75 °C, about 76 °C, about 77 °C, about 78 °C, about 79 °C, about 80 °C, about 81 °C, about 82 °C, about 83 °C, about 84 °C, about 85 °C, about
• a useful thermostable Cas protein performs (e.g., its collateral cleavage activity functions sufficiently) within a temperature range at which nucleic acid extension and/or amplification reaction(s) are performed; those skilled in the art are well familiar with various such reactions and the temperature ranges at which they are performed,
• a temperature range may be above a temperature selected from the group consisting of about 60 °C, about 61 °C, about 62 °C, about 63 °C, about 64 °C,65 °C, about 66 °C, about 67 °C, about 68 °C, about 69 °C, about 70 °C, about 71°C, about 72 °C, about 73 °C, about 74 °C, about 75 °C, about 76 °C, about 77 °C, about 78°C, about 79 °C, about 80 °C, about 81 °C, about
• a temperature range may be about 60 °C to about 90 °C. In some embodiments, a temperature range may be about 60 °C to about 80 °C. In some embodiments, a temperature range may be about 60 °C to about 75 °C. In some embodiments, a temperature range may be about 65 °C to about 90 °C. In some embodiments, a temperature range may be about 60 °C to about 80 °C. In some embodiments, a temperature range may be about 60 °C to about 75 °C.
• thermostable thermostable resin in some embodiments, a useful thermostable thermostable
• Cas protein is a Casl2 or Casl3 homolog (e.g., ortholog), e.g., a Cas enzyme comprising an amino acid sequence having 80%, 85%, 90%, 99% or 100% sequence identity to any one of SEQ ID Nos. 1-283 that is thermostable at temperatures above about 50 °C, and in some embodiments above about 60 °C, for example within and/or above about 60-65 °C.
• thermostable Cas protein is a Cas 12 (e.g, SEQ ID NO 3-21, 33-47, 51-56, 68-178, and 274-283, or a variant thereof, for example having at least 90%, 95%, 99% or greater amino acid sequence identity thereto) or Casl3 (e.g., SEQ ID NO 1-2, 22-32, 48-50, 57-67, 179-273, or a variant thereof, for example having at least 90%, 95%, 99% or greater amino acid sequence identity thereto) whose activity (e.g., whose target binding and collateral cleavage activities) is sufficiently thermostable, for example at temperatures within a range of 60-65 °C to perform in assays as described herein (e.g, in some embodiments, one-pot assays).
• sufficient thermostable activity is activity that is reasonably comparable to (e.g., within about 25%)
• the disclosure describes a detection method comprising steps of: contacting a CRISPR-Cas complex comprising: a Cas protein with collateral cleavage activity that is thermostable at temperatures above at least 60- 65 °C; and a guide RNA selected or engineered to be complementary to a target sequence; with a sample potentially comprising a nucleic acid of the target sequence.
• the step of contacting comprises contacting the
• a detection method further comprises a step of amplifying nucleic acid present in the sample.
• the step of amplifying utilizes a thermostable nucleic acid polymerase.
• the steps of amplifying and contacting are performed in a single vessel.
• the Cas protein is a Casl2 protein.
• the Cas protein has an amino acid sequence that is at least 80% identical to that of SEQ ID NO: 15.
• the Cas protein has an amino acid sequence having at least 80%, sequence identity to any one of SEQ ID Nos. 3-21, 33- 47, 51-56, 68-178, and 274-283.
• the Cas protein has an amino acid sequence having 80%, sequence identity to any one of SEQ ID Nos. 1-283.
• the improvement that comprises utilizing a Cas protein with thermostable collateral cleavage activity comprises utilizing a Cas protein with thermostable collateral cleavage activity.
• the Cas protein is a Cas 12 protein.
• the Cas protein has an amino acid sequence that is at least 80% identical to that of SEQ ID NO: 15.
• the Cas protein has an amino acid sequence having at least 80%, sequence identity to any one of SEQ ID Nos. 3-21, 33-47, 51-56, 68-178, and 274-283.
• a method of performing a detection assay is conducted in a single reaction vessel.
• thermostable collateral cleavage activity is thermostable above a temperature of about 60°C. In some embodiments, the thermostable collateral cleavage activity is thermostable above a temperature of about 65°C. In some embodiments, the Cas protein has an amino acid sequence having at least 80% sequence identity to any one of SEQ ID Nos. 1-283.
• Figures 1 A and IB document the insight, provided by the present disclosure that certain Casl3 protein(s) are insufficiently stable at relevant temperature(s), e.g., at temperatures at which nucleic acid extension and/or amplification reactions are typically performed (e.g., above about 60-65 °C).
• Figure 2 documents the insight, provided by the present disclosure that certain Casl2 protein(s) are insufficiently stable at relevant temperature(s), e.g., at temperatures at which nucleic acid extension and/or amplification reactions are typically performed (e.g., above about 60-65 °C).
• FIG 4 displays an exemplary method for discovery and screening of thermostable Cas enzyme candidates (e.g., Casl2 and Cas 13 enzymes)
• thermostable Cas enzyme candidates e.g., Casl2 and Cas 13 enzymes
• Figure 5 displays an exemplary assessment of Casl2a candidate enzymes by endpoint assay.
• Figure 6 displays an exemplary assessment of Cas 12a candidate enzymes by kinetic assay.
• Figure 7 displays an exemplary assessment of candidate enzymes at 58°C by endpoint and kinetic assays.
• Figure 8 displays an exemplary assessment of candidate enzymes at 60°C by endpoint and kinetic assays.
• Figure 9 displays an exemplary assessment of candidate enzymes at 62°C by endpoint and kinetic assays.
• Figure 10 displays exemplary assessment of four candidate enzymes that were purified and activity was measured at varying temperatures (e.g., approximately 35°C to approximately 65°C).
• Figure 11 shows exemplary characterization of a subset of enzyme candidates using three different guide and target sets compared to no template control at both 58°C and 70°C.
• Figure 12 shows exemplary characterization of a Cast 2 candidate enzyme with multiple guide/target pairs at both 52°C and 58°C.
• Figure 13 demonstrates kinetic assays for a Casl2a candidate enzyme
• Figure 14 displays characterization of Casl3 candidate enzymes by endpoint assay at both 37°C and 52°C.
• FIG. 15 displays exemplary thermostable Casl2a enzyme, RS9, requires
• TGRR Thermostable Inorganic Pyrophosphatase
• FIG 16 demonstrates exemplary thermostable Casl2a enzyme, RS9, is specific for its target and requires TIPP for amplification.
• Amplification was conducted with a starting concentration of 4,500 copies/pL ORFlab template and either primers and guides specific to ORFlab or non-targeting primers with an ORFlab guide. Each reaction condition was also conducted in the presence or absence of TIPP.
• Figure 17 demonstrates exemplary thermostable Casl2a enzyme, RS9, displays collateral cleavage activity.
• Figure 18 demonstrates RS9 collateral cleavage activity compared to known
• FIG. 19 demonstrates characterization of exemplary thermostable Casl3a enzyme, TccCasl3a.
• Optimal temperature for TccCasl3a activity was determined using a Cas reaction over a range of temperatures. Temperature profiles suggest TccCasl3a shows highest activity at approximately 62°C.
• FIG. 20 demonstrates TccCasl3a can be activated by RNA, but cannot be activated by ssDNA, even at the highest concentrations of ssDNA.
• FIG. 21 displays TccCasl3a activation requires a higher concentration of ssDNA than RNA, similar to that observed for LwaCasl3 ssDNA activation.
• TccCasl3a was not activated by ssDNA* at any concentration (10 nM, 100 nM, or 1,000 nM) compared to control.
• Figure 22 demonstrates that TccCasl3a shows increased collateral activity at “NN” sites compared to “UU” sites, while LwaCasl3a shows no preference for collateral activity of “NN” sites compared to “UU” sites.
• Figure 23 demonstrates exemplary characterization of candidate thermostable Cas enzymes, Pall, Pal2 low MW, Pal2 high MW, and Pal3.
• Figure 24 demonstrates exemplary Pall and Pal2 activity at 56°C.
• Figure 25 demonstrates exemplary activity of Pall at 37°C, 56°C, and 70°C with different exemplary guides.
• Figure 26 demonstrates exemplary activity of Pall at 56°C and 70°C compared to control. These data suggest activity of Pall is specific to target DNA.
• Figure 27 demonstrates exemplary temperature profile of Pal 1.
• Figure 28 demonstrates exemplary activity of Pal2 high MW at 37°C, 56°C, and 70°C with different exemplary guides.
• Figure 29 demonstrates exemplary activity of Pal2 high MW at 56°C compared to control. These data suggest activity of Pal2 high MW is specific to target DNA.
• Figure 30 demonstrates exemplary temperature profile of Pal2 high MW.
• Formats of particular interest include Casl3-based (e.g., Casl3a- or
• Casl3b- based systems including those referenced as “SHERLOCK” and/or “HUDSON” systems (see, for example, Gootenberg et al, Science 356:438, 2017; Gootenberg etal , Science 360:339, 2018; Myhrvold etal., Science 360:444, 2018; see also US 10266887) and Cas 12- based (e.g., Casl2a- or Casl2b-based) systems, including those references as “HOLMES” or “DETECTR” systems (see, for example, Cheng et al. CN patent filing CN107488710A; PCT/CN 18/82769 and US 16/631,157; Li et al. Cell Disc. 4:20, 2018; Chen et al. Science 360:436, 2018; Li, L. et al. bioRxiv Published online July 26, 2018. http://dx. doi.org/10.1101/362889; US10253365).
• typical detection assays that utilize Cas protein collateral cleavage activity involve contacting an appropriate CRISPR-Cas complex, including a Cas protein with collateral activity and a guide RNA complementary to a target sequence of interest, with a sample that may contain the target sequence.
• an appropriate CRISPR-Cas complex including a Cas protein with collateral activity and a guide RNA complementary to a target sequence of interest
• the Cas protein Upon recognition of the target sequence, the Cas protein’s collateral activity is activated, so that it cleaves unrelated nucleic acid (DNA or RNA or both, depending on the enzyme).
• a reporter of the relevant cleavable nucleic acid is provided, appropriately configured (e.g., labeled) so that its cleavage as a result of the activated collateral activity is detectable (e.g., separates a fluorophore from a quencher so that fluorescencebecomes detectable, etc).
• a target sequence is generated and/or amplified (e.g., copied from RNA to DNA and/or amplified, for example by primer extension, DNA replication (e.g., by polymerase chain reaction) and/or transcription). See, for example, Figures 3 and 4 of the above-mentioned Li Review (Li et al Trends Biotechnol. 37:730, July 2019).
• a collateral activity assay includes steps of
• target copying and/or amplification (2) target binding; and (3) signal release and/or detection.
• collateral activity assays as described herein are in vitro assays.
• they may be cell free assays (e.g., may be substantially free of intact cells, or, in some embodiments, of cell fragments).
• collateral activity assays as described herein are performed on samples that are or are prepared from biological (e.g., blood, saliva, tears, urine, etc) or environmental (e.g., soil, water, etc) primary samples.
• biological e.g., blood, saliva, tears, urine, etc
• environmental e.g., soil, water, etc
• the present disclosure identifies the source of a problem with certain detection (e.g., diagnostic assays) that utilize Cas protein collateral activity, as described above, in that certain Cas proteins with collateral activity are insufficiently stable at relevant temperatures (e.g., at temperatures at which nucleic acid extension and/or amplification are performed). Additionally, the present disclosure further surprisingly demonstrates that, for some proteins, loss of activity upon temperature elevation may be irreversible. This reality increases the significance of the insight, provided by the present disclosure, that Cas proteins with thermostable collateral activity are particularly desirable for use in assays asia described herein. Figures 1 and 2 document these findings.
• the present disclosure therefore provides improved detection (e.g., diagnostic) assays that utilize Cas protein collateral activity, which improved assays utilize a thermostable Cas protein (e.g., whose collateral activity is thermostable) as described herein.
• detection e.g., diagnostic
• thermostable Cas protein e.g., whose collateral activity is thermostable
• steps of nucleic acid detection and target binding are performed in a single vessel; in some embodiments, steps of target binding an signal release are performed in a single vessel; in some embodiments, steps of steps of (1) target copying and/or amplification; (2) target binding; and (3) signal release and/or detection are performed in a single vessel; in some embodiments all steps are performed in a single vessel - i.e., provided improved assays are one-pot assays.
• improved collateral activity assays as described herein are in vitro assays. In some embodiments, they may be cell free assays (e.g., may be substantially free of intact cells, or, in some embodiments, of cell fragments).
• improved collateral activity assays as described herein are performed on samples that are or are prepared from biological (e.g., blood, saliva, tears, urine, etc) or environmental (e.g., soil, water, etc) primary sample.
• biological e.g., blood, saliva, tears, urine, etc
• environmental e.g., soil, water, etc
• a Cas enzyme with thermostable collateral cleavage activity is a homolog (e.g., ortholog) of a Cas enzyme that either does not have demonstrable collateral cleavage activity, or has demonstrable collateral cleavage activity but loses such activity above a relevant temperature as described herein.
• a Cas enzyme with thermostable collateral cleavage activity as described herein is a Casl2 (e.g., Casl2a or Casl2b) enzyme.
• a Cas enzyme with thermostable collateral cleavage activity as described herein is aCas!3 (e.g., Casl3a or Casl3b) enzyme.
• a Cas enzyme with thermostable collateral cleavage activity as described herein is a Cas enzyme comprising an amino acid sequence having 80%, 85%, 90%, 99% or 100% sequence identity to any one of SEQ ID Nos. 1-283.
• improved collateral activity assays as described herein are performed using a Cas enzyme comprising an amino acid sequence having 80%, 85%, 90%, 99% or 100% sequence identity to any one of SEQ ID Nos. 1-283.
• nucleic acids from an infectious agent (e.g., a virus, microbe, parasite, etc), nucleic acids indicative of a particular physiological state or condition (e.g., presence or state of a disease, disorder or condition such as, for example, cancer or an inflammatory or metabolic disease, disorder or condition, etc), prenatal nucleic acids, etc.
• infectious agent e.g., a virus, microbe, parasite, etc
• nucleic acids indicative of a particular physiological state or condition e.g., presence or state of a disease, disorder or condition such as, for example, cancer or an inflammatory or metabolic disease, disorder or condition, etc
• prenatal nucleic acids e.g., prenatal nucleic acids, etc.
• a target nucleic acid is detected by an assay comprising a Cas enzyme as described herein and a cRNA.
• the structure of the cRNA can affect the activity of the Cas/cRNA complex.
• the structure of the Cas/cRNA complex contributes to the thermostability of the Cas collateral activity.
• the sample is a biological sample; in some embodiments, a sample is an environmental sample. In some embodiments, a sample is a crude sample (e.g., a primary sample or a sample that has undergone minimal processing).
• a sample will be processed (e.g., nucleic acids will be partially or substantially isolated or purified out of a primary sample); in some embodiments, only minimal processing will have been performed (i.e., the sample will be a crude sample).
• Example 1 Temperature profile for LwaCasl3a
• thermostability ofLwaCasl 3a was tested. Briefly, labeled RNA target was incubated with Rnase Inhibitor; T7 RNA Polymerase, LwaCasl3a, MgC12 and a cRNA. Individual samples were incubated at various temperatures to determine collateral activity.
• Figure 1 A presents a temperature profile for LwaCasl 3a collateral activity. As can be seen, low activity was observed above 45 °C; activity was completely abolished about 55 °C.
• figure IB presents results of testing the reversibility of loss of
• thermostability of AsCas 12a and Lbacas 12a was tested. Briefly, labeled RNA target was incubated with Rnase Inhibitor; T7 RNA Polymerase, AsCasl2a or Lbacasl2a, MgC12 and a cRNA. Individual samples were incubated at various temperatures to determine collateral activity.
• Figure 2 presents temperature profiles for AsCasl2a and LbaCasl2a. As can be seen, low AsCasl2a activity is observed at temperatures greater than 55 °C. AsCasl2a remains active at 60°C for ⁇ 5min. AsCasl2a has ⁇ 10% activity at 65°C for a few minutes. Further, LbaCasl2a activity is significantly diminished at temperatures greater than 55 °C.
• the present Example describes certain thermostable Cas 13 candidates for use in improved collateral activity assays as described herein.
• Exemplary sequences for use with TccCasl3a include, but are not limited to:
• Agtgtctttgcaggaaagaacacagatcttgagggtcacaactcccatgtaggcggagactgcaacccctatagtgagtc gtattaatt tc (SEQ ID NO. :284) (forward DR crRNAs); and agtgtctttgcaggaaagaacacagatcttgagggttgcagtctccgcctacatgggagttgtgacccctatagtgagtcg tattaat ttc (SEQ IDNO.:285) (reverse complement DR crRNAs);
• ThpCasl3a Thalassospira profundimaris
• Exemplary sequences for use with ThpCasl3a include, but are not limited to:
• Tctttgcaggaaagaacacagatcttgaggggtgtagttcccctcaatttggggatgaacgtcgacccctatagtgagtcgt attaat ttc (SEQ ID NO.:286) (forward DR crRNAs); and tctttgcaggaaagaacacagatcttgagggtcgacgttcatccccaaattgaggggaactacaccccctatagtgagtcg tattaa tttc(SEQ ID NO. :287) (reverse complement DR crRNAs);
• BhCasl2b (Bacillus hisashii )
• LsCasl2b (Laceyella sediminis)
• Exemplary sequences for use with AacCasl2b include, but are not limited to: ttgtgagcggataaacacaggtgccacttctcagatttgagaagctcaacgggctttgccacctggaaagtggccattggca caccc gttgaaaattctgtcctctagacccctatagtgagtcgtattaatttc(SEQ ID NO.:288) (crRNA)
• Exemplary sequences for use with AkCasl2b include, but are not limited to:
• Exemplary sequences for use with BhCasl2b include, but are not limited to: aattgtgagcggataaacacaggtgctaatgcctcccctatagtgagtcgtattaatttc(SEQ ID NO.:291) (crRNA); and gagacatcgtccagcaataggagtttctcacaccctgcagcacttatagctagacggttgtcctgaccaaaagacagaacc cctata gtgagtcgtattaatttc(SEQ ID NO.:292) (tracrRNA)
• Exemplary sequences for use with LsCas 12b include, but are not limited to:
• Atggtcatagctgtttcctgtgtttatccgctcagtgctaatcacatttaattcatctaccctatagtgagtcgtattaattt c SEQ ID NO. :293 (crRNA).
• Gataaataatgtaatcctgtggttgaatggatttttccatccttagcacacgcacagtattctttgccctttaggcaaaccct atagtg agtcgtattaatttc (tracrRNA).
• Exemplary sequences of Cas proteins with thermostable collateral activity include those described in Table 1 :
• Table 1 Exemplary sequences of Cas proteins with thermostable collateral activity
• thermostable Cas 13 candidates for use in improved collateral activity assays as described herein.
• the thermostability of TccCasl3a and ThpCasl3a was tested. Briefly, varying ranges of labeled RNA target was incubated with TccCasl3aor ThpCasl3a; Rnase Inhibitor; T7 RNA Polymerase, MgC12 and a cRNA (either in forward or reverse complement orientation).
• Figure 3 A demonstrates the significant activity of TccCasl3a at 65°C.
• the data of Figure 3A also suggests the structure of the cRNA can influence the activity of thermostable enzymes.
• figure 3B demonstrates that TccCasl3a is active across a wide range of temperatures including the range 40°C to 65°C.
• Example 5 Exemplary discovery and screening for thermostable Cas enzymes
• thermostable Cas enzyme candidates e.g ., Casl2 and Casl3 enzymes
• Novel Casl2 and Cas 13 enzymes were discovered using a custom-built in silico pipeline.
• publicly available microbial genomes and metagenome databases were first filtered on the basis of environmental metadata such as sample collection temperature and sequencing read quality.
• CRISPR repeats were subsequently identified in the filtered genomic datasets using published repeat annotation methods.
• Candidate enzymes were expressed by in vitro protein synthesis (e.g.
• a subset of candidates e.g., 12 candidates that demonstrated highest activity among the 44 initial candidates at 52°C were selected in combination with their most efficient guide and target for further assessment at higher temperatures (e.g., 58°C, 60°C, 62°C).
• Example 6 Exemplary characterization of a thermostable Casl2a enzyme
• thermostable Casl2a enzyme RS9.
• TIPP Thermostable Inorganic Pyrophosphatase
• An exemplary reaction included 30 ng/ul RS9, 112.5 XL-213 (ORFlab guide), lx HKFB (ORFlab) primer set, lx wsLAMP mix, 125 nM DNase Alert, with or without 1 U Thermostable Inorganic Pyrophosphatase (TIPP) with indicated viral RNA template concentration present.
• the exemplary reaction was incubated at 58°C for 120 minutes on QS5 with detection in VIC channel. Real-time reactions that did not contain TIPP resulted in no statistically significant amplification of ORFlab compared to the no template control regardless of the starting concentration of template.
• RS9 Specificity of RS9 was also assessed using real-time analysis. Amplification was conducted with a starting concentration of 4,500 copies/pL ORFlab template and either primers and guides specific to ORFlab or non-targeting primers with an ORFlab guide. Each reaction condition was also conducted in the presence or absence of TIPP.
• An exemplary reaction included 30 ng/ul RS9, 112.5 XL-213(ORFlab guide), lx HKFB (ORFlab) or CFB (N) primer set, lx wsLAMP mix, 125 nM DNase Alert, with or without 1 U Thermostable Inorganic Pyrophosphatase (TIPP), with 4,500 copies/m ⁇ viral RNA present.
• RS9 collateral cleavage activity was assessed using 100 nM of single stranded DNA target and DNaseAlert or RNaseAlert as reporters. A no target condition was utilized as a negative control. RS9 was unable to cleave DNaseAlert, resulting in intensity measurements significantly above no target control conditions. RS9 was able to cleave RNaseAlert, resulting in measured intensity similar to that of the no target control conditions, indicating RS9 has RNA-specific collateral cleavage activity (Figure 17)
• Example 7 Exemplary characterization of a thermostable Casl3a
• thermostable Casl3a enzyme TccCasl3a.
• TccCasl3a thermostable Casl3a enzyme
• TccCasl3a could be activated by ssDNA in addition to RNA
• a Cas reaction was completed at 62°C with RNaseAlert as a reporter.
• Different targets were utilized at different concentrations (e.g 10 nM, 100 nM, or 1,000 nM ssDNA or 10 nM RNA).
• a no target condition was utilized as a negative control.
• TccCasl3a activation by ssDNA was also assessed at 58°C.
• TccCasl3a was activated at 58°C in the presence of 1 nM, 10 nM, and 100 nM RNA target compared to no target control, while TccCasl3a activation by ssDNA at 58°C was only detected when 100 nM or 1,000 nM of ssDNA target was utilized.
• 10 nM of ssDNA target at 58°C showed no difference compared to no target control, suggesting TccCasl3a activation requires a higher concentration of ssDNA than RNA, similar to that observed for LwaCasl3 ssDNA activation.
• TccCasl3a was not activated by ssDNA* at any concentration (10 nM, 100 nM, or 1,000 nM) compared to control (no target) ( Figure 21).
• Example 8 Exemplary characterization of additional candidate thermostable Cas enzymes
• the present example demonstrates characterization of exemplary thermostable Cas enzymes, Pall (SEQ ID NO. 274), Pal2 low MW, Pal2 high MW (SEQ ID NO. 275), and Pal3 (SEQ ID NO. 276).
• Each enzyme was tested with four guides (designated as 342-353) at both 37°C and 56°C in a Cas-only reaction with DnaseAlert as a reporter. Fluorescence signal was plotted vs. time for each reaction ( Figure 23).
• Pall showed low activity for two guides at 56°C. No activity was observed for Pal2 low MW or Pal3, while activity was observed for two guides at 56°C for Pal2 high MW.
• Pall and Pal2 activity at 56°C is shown in Figure 24. Additional results of studies with these enzymes are shown in Figures 25-30. As can be seen, Pall showed activity for 2 guides at 56°C and 70°C; Pall showed maximum activity at 57°C and significant activity to at least 67°C.
• Pal2 high MW showed activity for 2 guides at 56°C; Pal2 high MW also showed maximum activity at 47-52°C and significant activity up to at least 57°C. No significant activity was observed for Pal2 low MW, or any of Pal3-6 at 37°C, 56°C, or 70°C.
• these enzymes are thermostable at least at about 56°C and/or within a range of 56°C and 70°C.
• These particular exemplified enzymes may also be described as thermoactive as their relevant activity(ies) are dramatically reduced and/or undetected at lower temperatures such as at 37°C. Without wishing to be bound by any particular theory, it is noted that enzymes of thermophilic organisms often may show reduced (or undetectable) activity at such temperatures.

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Biomedical Technology (AREA)
• Analytical Chemistry (AREA)
• Immunology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Plant Pathology (AREA)
• Medicinal Chemistry (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
• Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Priority Applications (12)

Applications Claiming Priority (10)

Related Child Applications (3)

Publications (1)

Family

ID=74858746

Family Applications (1)

Country Status (11)

Cited By (11)

Families Citing this family (1)

Citations (6)

Family Cites Families (5)

• 2021
  • 2021-01-27 AU AU2021212731A patent/AU2021212731A1/en active Pending
  • 2021-01-27 IL IL295011A patent/IL295011A/en unknown
  • 2021-01-27 MX MX2022009212A patent/MX2022009212A/es unknown
  • 2021-01-27 KR KR1020227027186A patent/KR20220131939A/ko active Pending
  • 2021-01-27 JP JP2022545378A patent/JP2023512985A/ja active Pending
  • 2021-01-27 WO PCT/US2021/015306 patent/WO2021154866A1/en not_active Ceased
  • 2021-01-27 US US17/795,815 patent/US20230183783A1/en not_active Abandoned
  • 2021-01-27 TW TW110103081A patent/TW202142698A/zh unknown
  • 2021-01-27 EP EP21710084.1A patent/EP4097250A1/en active Pending
  • 2021-01-27 BR BR112022014777A patent/BR112022014777A2/pt unknown
  • 2021-01-27 CA CA3168830A patent/CA3168830A1/en active Pending
• 2022
  • 2022-11-18 US US17/990,565 patent/US20230272458A1/en not_active Abandoned
• 2025
  • 2025-03-14 US US19/080,542 patent/US20250327116A1/en active Pending

Patent Citations (7)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events